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Abstract
Background: Colorectal cancer (CRC) screening using a faecal occult blood test (FOBt) 
has the potential to reduce cancer- related mortality. Symptom vigilance remains cru-
cial as a proportion of cancers will be diagnosed between screening rounds. A negative 
FOBt has the potential to influence how participants respond to future symptoms of 
CRC.
Objective: To explore (i) understanding of a negative FOBt and (ii) the potential impact 
of a negative FOBt upon future symptom appraisal and help- seeking behaviour.
Design: Qualitative methodology utilizing focus groups with participants who received 
a negative FOBt within the National Bowel Cancer Screening Programme in Coventry 
and Lothian. Topics explored included: experience of screening participation, interpre-
tation and understanding of a negative result, symptom awareness and attitudes 
towards help-seeking.
Results: Four broad themes were identified: (i) emotional response to a negative FOBt, 
(ii) understanding the limitations of FOBt screening, (iii) symptom knowledge and 
interpretation and (iv) over- reassurance from a negative FOBt. Participants were reas-
sured by a negative FOBt, but there was variability in the extent to which the result 
was interpreted as an “all clear”. Some participants acknowledged the residual risk of 
cancer and the temporal characteristic of the result, while others were surprised that 
the result was not a guarantee that they did not have cancer.
Discussion and conclusions: Participants recognized that reassurance from a negative 
FOBt could lead to a short- term delay in help-seeking if symptoms developed. 
 Screening programmes should seek to emphasize the importance of the temporal 
nature of FOBt results with key messages about symptom recognition and prompt 
help-seeking behaviour.
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1  | INTRODUCTION
In the United Kingdom, colorectal cancer (CRC) is the fourth most 
common cancer and is the second most common cause of cancer 
death.1,2 There is a growing body of evidence that early diagno-
sis of CRC leads to more favourable outcomes,3–6 with a number of 
countries introducing CRC screening programmes for the general/
average risk population. Biennial CRC screening using a guaiac faecal 
occult blood test (gFOBt) was first rolled out nationally in Scotland 
in 2006, with complete coverage by 2010, and similar programmes 
were introduced across the rest of the United Kingdom at the same 
time. A positive test result indicates that further investigation (usual-
ly a colonoscopy) is required.7 The most recent Cochrane review on 
CRC screening using gFOBt suggests a 15% relative risk reduction in 
CRC mortality for trials that used biennial screening.8 In the United 
Kingdom the majority of the screened population receive a negative 
gFOBt result, while approximately 2% of the population receive a pos-
itive result fewer than 10% of these (0.2%) are attributable to CRC.9,10
Some CRCs do not lose sufficient blood to be detected by a gFOBt 
which can result in low sensitivity,11 reported to be down to 0.55 in 
randomized controlled trials (RCTs).8 Pilot screening programmes and 
trials in the United Kingdom have reported a false- negative proportion 
between 30% and 50%.9,12,13
Interval cancers are defined as “CRC diagnosed after a screening 
or surveillance episode in which no cancer is detected, and before 
the date of the next recommended test”.14,15 Thus, CRC screening 
using gFOBt misses a proportion of cancers, and cancers can develop 
between screening rounds—even with a fully implemented screening 
programme up to 75% of all CRC’s will be diagnosed following symp-
tomatic presentation.16 It is therefore important that screening pro-
grammes run alongside diagnostic pathways, particularly in general 
practice, to ensure early symptomatic presentation and timely referral.
Participation in screening has the potential to influence how 
individuals respond to bowel symptoms, but to date, there is lit-
tle evidence to suggest how a negative test result might influence 
symptom appraisal and help- seeking behaviour. A recent UK study 
of patients with symptoms suggestive of CRC found that a recent 
negative screening test result was perceived to be reassuring, partic-
ularly if cancer had been considered as a possible cause of the experi-
enced symptoms.17 In cervical cancer screening, one study found that 
only 52% of women correctly understood that a “normal” test result 
entailed a residual risk of cervical cancer.18 Solbjør et al. (2012)19 
reported that some women who experienced possible symptoms of 
breast cancer delayed help-seeking if symptoms occurred following a 
recent negative mammography scan because they assumed that their 
palpable lesion would be benign.
In summary, to date, there is a paucity of research investigating 
understanding of a negative gFOBt result among bowel screening par-
ticipants. The purpose of this study was to explore (i) how a negative 
gFOBt result is understood by screened participants and (ii) in what 
ways a negative gFOBt result might impact upon future symptom 
appraisal and help- seeking behaviour if symptoms develop.
2  | METHODS
2.1 | Study design
A focus group study with individuals who had participated in the bow-
el cancer screening programmes in Scotland (Lothian) and England 
(Coventry) within the last 4 months and whose result was negative. 
Focus groups were chosen to allow for the exploration of a broad and 
diverse range of viewpoints and to encourage discussion between 
participants to help draw out any latent issues.
2.2 | GP practice recruitment
Focus group participants were recruited via their general practice on 
behalf of the research team. Two practices were recruited in Lothian, 
Scotland, and five in Coventry, England. Practices were recruited via the 
National Institute for Health Research (NIHR) Clinical Research Network 
(England) or established research links (Scotland). Practices were pur-
posively selected to include varied locations, for example both inner 
and outer city practices and a mix of deprived and affluent postcodes. 
Practice selection was informed by publically available information on 
practice demographics (Information Services Division, Scotland, and 
Public Health England websites) and advice from the local primary care 
research team (Lothian) and NIHR (Coventry) who had a local knowl-
edge of the geographical area and were familiar with the practice popu-
lations served by each practice. A modest monetary reimbursement was 
offered to practices in exchange for assisting with study recruitment.
2.3 | Participant recruitment
Practice staff generated a list of approximately 60 individuals who 
had participated in bowel screening and received a negative gFOBt 
result within the previous 4 months (extended to 6 months for prac-
tices with a smaller list size). Sixty individuals were selected based on 
a 10%–15% response rate achieved in a similar study, led by Weller 
et al., University of Edinburgh, that recruited healthy participants in 
this age group via general practices to participate in a focus group—
manuscript in preparation. Practice staff were responsible for patient 
identification based on the inclusion/exclusion criteria provided 
by the research team. These individuals were sent an invitation let-
ter from the GP practice on behalf of the research team including 
an information leaflet, response form, consent form and a pre- paid 
return envelope. Based on the literature and prior experience in focus 
group research, the research team anticipated that between six and 
eight focus groups (comprising of six to eight individuals) would be suf-
ficient to provide a range of views and reach theoretical saturation.20
Once a response form was returned, participants were contacted 
by the researcher to confirm a time and date for the focus group to 
take place. Focus groups were held on the general practice premises. 
At the end of each focus group, participants were given an information 
leaflet about CRC and offered a £15 high street voucher to thank them 
for their contribution.
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2.4 | Exclusion criteria
Practice staff were asked to exclude potential participants if they had 
a recent bereavement, a recent cancer diagnosis (any) or were cur-
rently undergoing any major treatments.
2.5 | Focus groups
Focus groups were carried out between July 2014 and November 
2014. Focus group discussions lasted between 60–90 minutes. Signed 
consent was obtained from each participant. Focus groups were audio- 
recorded, professionally transcribed verbatim and anonymized. Audio 
files were deleted once the written transcripts had been received and 
verified by the researcher. Topics explored in the focus group includ-
ed the following: experience of screening participation, interpretation 
of a negative result, understanding of the limitations of the gFOB test, 
symptom awareness and attitudes towards help-seeking.
2.6 | Ethical review
The project was granted ethical approval from the South East Scotland 
Research Ethics Committee 01 (11/SS/0006), on 26 August 2011.
2.7 | Patient and public 
involvement and engagement
Patient and public involvement and engagement in this project came 
through discussion of the design and interpretation of results with lay 
members of the South East of Scotland Primary Care (SCAN) Network.
2.8 | Analysis
Thematic analysis of the data was undertaken (KB) using NVivo qualita-
tive data analysis Software; QSR International Pty Ltd. Version 10, 2012 
and was on- going throughout the study to allow emerging themes to be 
fed back into the data collection. An inductive reasoning approach was 
adopted where themes (or categories) were identified through careful 
examination and comparison of the data.21 To ensure inter- rater reliabil-
ity, a second member of the research team (CC) read all focus group tran-
scripts and independently coded two transcripts, emerging issues were 
discussed, and a coding frame agreed. Additional codes were added to 
the coding frame as appropriate. Final themes were agreed through an 
iterative process involving the core and wider research group. The analy-
sis focused on the main themes surrounding the interpretation and influ-
ence of a negative gFOBt result on future help- seeking behaviour.
3  | RESULTS
3.1 | Recruitment
Six focus group were carried out, two in Lothian, Scotland, and four 
in Coventry, England. Between 3 and 10 participants attended each 
focus group, with a total of 35 participants (16 male) taking part. A 
summary of participant demographics and demographics of the recruit-
ing general practices in Lothian and Coventry are provided in Table 1. 
Core themes were common to all of the focus groups, and no new 
themes were emergent as the sixth focus group was analysed.
3.2 | Findings
The majority of participants who attended a focus group had engaged 
in more than one round of CRC screening with high experience of the 
the bowel cancer screening programmes. Across all six focus groups, 
screening was viewed positively among the participants with general 
agreement on the importance, or benefits, of the early detection of 
cancer with some acknowledging the importance of continued partici-
pation in cancer screening.
Four broad themes emerged from the focus group analysis, 
each with a number of influencing factors (subthemes): (i) emotional 
response to a negative gFOBt result (anticipation of test result, fam-
ily history, competing diagnoses); (ii) understanding the limitations of 
gFOBt screening (recall of screening information); (iii) symptom knowl-
edge and interpretation (family history, competing diagnoses and non- 
cancer suspicion); and (iv) whether there was over- reassurance from 
a negative gFOBt. Together these contributed to how participants 
understood a negative gFOBt and the impact on future symptom 
appraisal and help- seeking behaviour. (See Fig. 1).
3.2.1 | Emotional response to a negative 
gFOBt result
Emotional response was influenced by three contributing factors (sub-
themes) including anticipation of their gFOBt result, for example wheth-
er or not they experienced any heightened anticipation or anxiety while 
awaiting their test result, family history of cancer and existing bowel 
concerns (competing diagnoses), for example irritable bowel syndrome 
(IBS).
In general, participants reported little, or no, apprehension while 
waiting to receive their result (normally within 2 weeks of complet-
ing their test kit), with some indicating that they had either forgot-
ten about it or had “put it to the back of their mind”. However, often 
external influences such as televised cancer awareness campaigns 
would act as a trigger and remind them that they were still awaiting 
their screening result. Higher levels of apprehension were described 
by those who had been asked to do a repeat screening test (usual-
ly requested in response to an uncertain test result or damaged/ 
incorrectly completed test kit) and by others who had a family histo-
ry of bowel cancer. For participants with a family history of cancer, 
heightened apprehension tended to be most pronounced the first 
time that they took part in the screening programme.
…my dad actually had bowel cancer and had to have part of 
his bowel removed, and although that didn’t kill him at the 
end, erm, that first, very first test when I sent it off, I was like 
a cat on hot bricks waiting for the result to come through.
(FG5: Female, Coventry)
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Participants indicated that they felt a positive emotion such as 
“relief” or “pleasure” when they received their negative gFOBt result. 
Others described receiving a negative result to simply “meet their 
expectation” as they viewed themselves to be healthy, were not 
experiencing symptoms and therefore did not express strong pos-
itive or negative emotions in response to receiving a negative test 
result.
Of course, yes, you just think, oh, you’ve, you’ve escaped 
the noose this time.
(FG4: Male, Coventry)
…with not having problems I, I wasn’t at all surprised when 
I got a negative result.
(FG2: Female, Coventry)
F IGURE  1  Identified themes and subthemes from the focus group analysis.
TABLE  1 Population demographics: focus group participants and recruiting general practices
Focus group (location) N (Male)
Age range (self- report: 5- year 
age categories) Previous cancer diagnosis (N) (self- report)
Participant demographics
1 (Coventry, England) 6 (3) 60–74 0
2 (Coventry, England) 3 (1) 60–69 1 (cervical)
3 (Lothian, Scotland) 6 (3) 50–74 1 (breast)
4 (Coventry, England) 6 (3) 60–69 2 (breast)
5 (Coventry, England) 10 (4) 60–74 1 (skin)
6 (Lothian, Scotland) 4 (2) 55–74 0
GP practice (FGs) Practice list size Location type Deprivation indicator
General practice demographics (serving invited population)36,37
England Deprivation Deciles (1 = most deprived; 
10 = least deprived)
Coventry (1 & 2) 10 912 Small Urban Area 4
Coventry (1 & 2) 8269 Outer City 2
Coventry (1 & 2) 8860 Inner City 6
Coventry (4) 5142 Outer Suburb 6
Coventry (5) 15 162 Outer Suburb 5
Scotland % Practice population living in data zones 
defined as the 15% most deprived
Lothian (3) 11 520 Small Urban Area <5
Lothian (6) 13 020 Inner City 43.2
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The feeling of relief or the reassurance felt having received a negative 
gFOBt result was more strongly conveyed in participants who had a fami-
ly history of bowel cancer or who had other bowel concerns such as IBS.
The doctor did several tests and he just told me that it is 
IBS and there’s nothing else for me to worry about. But, 
erm, I do like doing the bowel test screening, because I 
think it just puts your mind at rest, if there’s bowel cancer 
or any type of cancer in the family, because it can come out 
in any way, shape or form.
(FG5: Female, Coventry)
3.2.2 | Understanding the limitations of 
gFOBt screening
A second broad theme to emerge was the extent to which partici-
pants understood or recognized the limitations associated with gFOBt 
screening. In part, this was dependent on their recall of the accom-
panying screening information provided with the screening test and 
result letter (subtheme). Participants were asked to think back to their 
negative (normal) test result letter and consider what they thought a 
negative result meant in terms of their CRC risk or the likelihood of 
developing symptoms in the future. When discussing the reliability 
of the test result, a number of participants indicated that they under-
stood that screening was not a 100% guarantee that they did not have 
cancer and that they could not rely on the test result alone. Several 
participants recalled the disclaimer in the result letter that stated they 
should visit their general practitioner if they experienced particular 
symptoms listed in the letter.
There’s a strong message that you don’t rely on that [nega-
tive gFOBt result] and do nothing for the next two years…
(FG3: Male, Lothian)
However, a number of participants were surprised to discover that a 
negative gFOBt was not a 100% guarantee that they did not have cancer, 
with some participants stating that they did not always read the screen-
ing materials sent to them with their screening test or result letter—this 
was particularly evident for those who had taken part in screening over 
a number of years. For example, when the researcher read aloud the 
paragraph that accompanied the negative test result letter sent out in 
Coventry, England, which stated that no screening test is 100% effective 
and that a negative test does not guarantee that you do not have cancer 
or will never develop bowel cancer in the future, one participant replied,
…that didn’t sink into me, I…you know, I wasn’t really 
aware that, you know, things could still go wrong. It didn’t 
come across to me too well, I just sort of sat there compla-
cent thinking, you know, I’m okay.
(FG2: Female, Coventry)
When asked why they felt the test was not 100% effective (or reli-
able), participants typically raised issues of “human error” and the belief 
that “nothing is perfect”—rather than attributing incorrect results to 
either the features of the test or to tumour characteristics that can some-
times lead to a cancer being “missed”.
I’m not saying that, you know, there’s lots of mistakes, but 
if you involve human beings, there’s always the possibility 
of an error, nobody is perfect…I just know that no screen-
ing is perfect.
(FG2: Female, Coventry)
Screening results are based on a specific time- point and may be dif-
ferent if screening is undertaken later. This temporal characteristic of a 
screening test result was recognized by some participants who indicated 
they understood that the test had not detected any signs of cancer at the 
time in which it was carried out, but recognized the possibility of “things 
going wrong” sometime thereafter. In three of the six focus groups, the 
time- limited nature of the test result was described to be like a Ministry 
of Transport (MOT) test which is an annual test for vehicle safety carried 
out in the United Kingdom.
…it’s like an MOT…it’s valid on the day that the car gets 
done and after that things start falling off again.
(FG3: Male, Lothian)
3.2.3 | Symptom knowledge and interpretation
The impact of receiving a negative gFOBt result on anticipated (hypo-
thetical) future symptom appraisal and help- seeking behaviour was 
partly influenced by participant’s existing knowledge of bowel can-
cer symptoms. The presence of a family history of cancer, competing 
bowel diagnoses and whether or not cancer was suspected contrib-
uted to how participants anticipated they might respond should they 
develop symptoms in the future. Participants unanimously felt that 
the introduction of screening programmes had increased their aware-
ness of CRC. Those who had personal experience of family or friends 
with cancer communicated a greater depth of knowledge about the 
significance of symptoms—particularly the more common alarm symp-
toms associated with CRC. A number of participants recognized that 
the presence of blood in stools was a potential indicator of bowel 
cancer, and many stated that a change in regular bowel habits was, 
or could be, a possible symptom. Participants did not readily associ-
ate more vague symptoms such as tiredness or abdominal pain with 
symptoms of CRC, and despite having taken part in the screening pro-
gramme, many for a number of years, a few participants disclosed that 
they felt they knew very little about the symptoms.
I wouldn’t have a clue.
(FG1: Male, Coventry)
Personally I don’t know what the symptoms are. I don’t 
know…other than, other than blood, or certainly anything 
like that, but I’ve got no idea at all.
(FG5: Male, Coventry)
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Participants recognized that competing bowel diagnoses such as IBS 
and haemorrhoids, and side- effects of some long- term medications, had 
the potential to mask possible cancer symptoms making symptom mon-
itoring and appraisal more difficult.
I have irritable bowel, so I find it quite difficult to spot. 
Because if they say, spot any changes [in your bowel hab-
its] mine changes on a daily basis.
(FG1: Female, Coventry)
Many participants had a positive attitude towards help-seeking and 
agreed that they would exhibit prompt help- seeking behaviours if they 
were to experience symptoms such as “blood in stool” or a change in 
their bowel movements. This was most strongly observed in participants 
with a family history of cancer. For less specific symptoms such as tired-
ness or abdominal pain, participants tended to describe more of a “watch 
and wait” self- monitoring approach, and some participants indicated that 
they would not wish to waste the doctors’ time for symptoms that they 
perceived to be less serious, or that they did not readily associate with 
a potential cancer diagnosis. The symptom characteristics described to 
have the most influence on the decision to seek help (visit a GP) were a 
combination of a perceived “change from what was normal” and “symp-
tom persistence” (rather than a “one-off” symptom). It was also suggested 
by some participants that experienced symptoms may not be perceived 
as bowel cancer symptoms but rather something that was “unusual” or 
“uncomfortable” and which they would like to seek advice.
Well, you have a feeling yourself what’s normal. And, I 
think if you notice a change that goes on, you know, per-
haps the odd day it doesn’t matter, but if it’s something 
that goes over a week or, or so, then I think you probably 
start to think, you know, what it could be.
(FG2: Male, Coventry)
I think the symptoms that would take you to the doctor, 
you might not necessarily be thinking, bowel cancer, but, 
you know, if things in your - for want of a better a word 
– plumbing start to go wrong, you might not necessar-
ily think, I’ve got bowel cancer but you would go along, 
because it’s…uncomfortable to live with if nothing else. 
Yeah.
(FG3: Male, Lothian)
3.2.4 | Whether there is over- reassurance from a 
negative gFOBt result
The fourth theme to emerge from the data centred on the prospect 
of “over- reassurance” following a negative gFOBt result and how tak-
ing part in CRC screening might inform the decision to visit a GP if 
participants later experienced symptoms. While many participants did 
not indicate that they felt that screening participation would influ-
ence their own help- seeking behaviour, participants recognized that 
a negative gFOBt result had the potential to contribute to a delay in 
help-seeking as a result of having been reassured by a recent negative 
result. Generally, any associated delay was attributed to how “others” 
might respond rather than how the participants themselves would 
respond, although some participants did indicate that they felt a nega-
tive gFOBt result might trigger a more optimistic approach in their 
own behaviour, leading them to potentially downplay symptoms or 
delay visiting their GP. Importantly, while participants felt that a nega-
tive gFOBt result might contribute to a delay in help-seeking in the 
short term, while they monitored rather than ignored symptoms, they 
did not believe that it would deter them from going to their doctor if 
symptoms persisted.
…you’d probably be worried less, but there would come 
a point where you, you decide you have to go and get it 
looked at. So, it might, it might just sort of, er, influence 
you a bit [receipt of a negative FOBT]
(FG2: Male, Coventry)
I’d think well I’ve just had a test I’m okay. But, if..the symp-
toms did…carry on…, BUT I think I tend to be, er, more 
optimistic and wouldn’t run to my doctors so quickly if I’d 
just had test results of negative.
(FG2: Female, Coventry)
4  | DISCUSSION
In this study, we explored how CRC screening participants understand 
and interpret a negative gFOBt result and whether receipt of a nega-
tive result has the potential to influence response to any future symp-
toms of CRC. There was variability in the extent to which a negative 
gFOBt result was interpreted as an “all clear”. While some participants 
acknowledged the residual risk of cancer associated with a negative 
gFOBt and the temporal nature of the test result, others were sur-
prised to learn that a negative result was not a guarantee that they did 
not have cancer. Participants recognized that reassurance following 
a negative gFOBt had the potential to contribute to a delay in help- 
seeking behaviour for symptoms suggestive of CRC, but overall par-
ticipants did not feel that it would deter them from visiting their GP if 
symptoms persisted.
Many participants who were asymptomatic approached screening 
from the perspective that a negative result was mere confirmation of 
their health state while for others, particularly if there was a family 
history of bowel cancer or other bowel concerns such as IBS, a neg-
ative result was associated with positive emotions (e.g. relief). These 
findings suggest that despite acknowledging screening is “not perfect”, 
most participants experienced some level of reassurance from their 
negative result.
In colorectal and other cancer screening programmes, reassurance 
can be an important motivator, and a psychological benefit associ-
ated with participation.22–24 However, over- reassurance can lead to 
negative consequences if, in turn, it influences a person’s response, 
for example, by downplaying important symptoms. This was evident 
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in the present study where some participants indicated that they felt 
their recent negative gFOBt result would lead them to be more opti-
mistic and delay going to see their GP. There are some parallels with 
other forms of screening: among women diagnosed with an interval 
breast cancer, participation in mammography screening has the poten-
tial to lead to a “postponed reaction” to breast cancer symptoms.19 
Similarly, over- reassurance from a previous “all clear” or non- cancer 
diagnosis following symptomatic presentation has been associated 
with delays in help-seeking for possible cancer symptoms due to new 
symptoms being normalized or interpreted as benign.25 The way in 
which people recognize, interpret and respond to symptoms is com-
plex and informed by a number of biopsychosocial, contextual and 
cultural influences,17 and therefore, reassurance or over- reassurance 
from a negative gFOBt is likely to be just one of a number of potential 
factors that influence a person’s decision to seek help for symptoms 
suggestive of CRC.
The study findings are consistent with a theoretical model of ill-
ness self- regulation that proposes that people respond to symptoms 
using an iterative process governed by their representation of symp-
toms associated with particular illness labels and by their experience 
during a process of “lay hypothesis testing”.26,27 The decision to con-
sult a doctor might be more likely if people have a clear representa-
tion of the illness label associated with a particular symptom set and 
a clear representation of appropriate action. In common with previous 
work,28 the present study found that alarm symptoms or symptoms 
that were feared to be linked to cancer as well as symptoms that per-
sisted over time were more likely to result in the decision to seek help. 
Furthermore, although not a prominent theme in the present study—
perhaps because behaviour was anticipatory, the influence of the 
social context, for example the role of family members or carers, on 
symptom interpretation and help- seeking behaviours could be further 
explored.
The results from the present study showed that some participants 
did not understand the nature of the limitations of gFOB screening in 
terms of the test or tumour characteristics7—the importance of which 
could be debated. Emphasis should be placed on the temporal nature 
of the test result with key messages around symptom recognition and 
advice about the benefits of prompt help-seeking, particularly as Hall 
et al.17 reported that, for some participants, a recent negative screen-
ing result was associated with a reluctance to consult with bowel 
symptoms. Participants in this study did recognize the importance of 
continued participation in the screening programme. The analogy used 
by some participants, who described gFOB testing to be “like a car 
MOT”, could provide a more appropriate understanding of screening, 
acknowledging both the cyclical nature of screening and the time- 
limited validity of the test result with the potential for things to still 
“go wrong” before the next screening round (or MOT) is due.
Participants who felt that their negative test result simply “met 
their expectations” attributed their response to a perception of “good 
health” and lack of experienced symptoms. In the screening literature, 
lack of symptoms has regularly been associated with lower perceived 
risk and lower uptake of cancer screening.29 This finding emphasizes 
the need for information that makes clear that the eligible population 
for cancer screening are asymptomatic individuals and that CRC can 
be diagnosed in those who perceive themselves to be fit and healthy.30
Family history of CRC and competing bowel diagnoses (primarily 
IBS in the present study, but potentially other bowel conditions such 
as Crohn’s disease and haemorrhoids) were important moderators 
cross- cutting a number of the study’s findings. Studies have shown that 
family history contributes to perceived risk of cancer31 but has been 
reported to contribute less when family history is either “unknown” or 
where family members have little or no contact.32 Reassurance from 
a negative gFOBt, in the presence of a family history or a competing 
bowel diagnosis, was heightened among the participants of this study. 
Competing bowel diagnoses also had the potential to mask possible 
symptoms of CRC. The complexities around symptom monitoring and 
symptom appraisal among participants of CRC screening who have 
existing bowel complaints or other morbidities are not well document-
ed and require further research.
It is important to note that this study explored participants’ antic-
ipated response (or intended behaviour) to future symptoms of CRC. 
The gap between good intentions and behaviour is well recognized 
in the psychological literature,33,34 and it is likely that participant’s 
intentions might differ from their actual behaviour in the presence of 
real symptoms. Our study participants were almost exclusively from a 
white ethnic background, many were retired, and we found that par-
ticipant attitudes towards screening were overwhelmingly positive. It 
is possible that participants may have been motivated to take part due 
to personal reasons that have increased their interest in this area or 
are more generally health aware than those who did not take up the 
invitation to attend a focus group. We did not have access to demo-
graphic information of those invited but who did not take part, to com-
pare with our study sample.
It is also possible that there is some discrepancy between what was 
disclosed in a group setting (public persona) and what some individuals 
felt personally (private persona) that was not disclosed in the focus 
group discussions. This is a limitation of all focus group research.35 
Similarly, participants’ opinions may have been influenced by the 
on- going discussions and their personal opinions may have changed 
throughout the course of the focus group.
5  | CONCLUSION
The importance of symptom vigilance between screening rounds is 
vital, given the limitations of gFOBt screening and the high incidence 
of interval cancers. Confidence in screening results has the potential 
to influence interpretation of symptoms and lead to a delay in help-
seeking. Effective early diagnosis and treatment might be further 
promoted by clear messages in information materials and result let-
ters regarding the time- limited value of the screening test and the 
nature of symptoms that should be reported to a GP. Further research 
might promote development of public health education materials that 
assist people in developing a mental representation of bowel symp-
toms. However, a major challenge for cancer screening programmes 
remains in finding new and innovative methods, that compliment 
8  |  
  
 Barnett et al.
on- going initiatives in primary care in promoting symptom awareness 
and prompt help- seeking behaviour, to deliver this information and 
engage with screening participants.
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